Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 245-253

  Geisler, Jürgen ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Estrogens; Exemestane; Letrozole; Tissue estrogens

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYTOKINE; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN SULFATASE; ESTROGEN SULFOTRANSFERASE; ESTRONE; EXEMESTANE; FORMESTANE; GROWTH FACTOR; LETROZOLE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VOROZOLE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER TISSUE; CELL SECRETION; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; ESTROGEN RELEASE; ESTROGEN SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MENOPAUSE; METASTASIS; NONHUMAN; POSTMENOPAUSE; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

EID: 0242659957     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00364-9     Document Type: Conference Paper

References (71)

1. Fishman J., Nisselbaum J.S., Menendez-botet C.J., Schwartz M.K. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J. Steroid Biochem. 8:1997;893-896.
2. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;1460-1464.
3. Vermeulen A., Deslypere J.P., Paridaens R., Leclercq G., Roy F., Heuson J.C. Aromatase, 17beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22:1986;515-525.
4. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
5. Blankenstein M.A., Maitimu-Smeele I., Donker G.H., Daroszewski J., Milewicz A., Thijssen J.H., On the significance of in situ production of oestrogens in human breast cancer tissue J. Steroid Biochem. Mol. Biol. 41:1992;891-896.
6. Bonney R.C., Reed M.J., Davidson K., Beranek P.A., James V.H. The relationship between 17beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin. Endocrinol. (Oxf.). 19:1983;727-739.
7. Chetrite G.S., Cortes-Prieto J., Philippe J.C., Wright F., Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 72:2000;23-27.
8. De Jong P.C., van de Ven J., Nortier H.W., Maitimu-Smeele I., Donker T.H., Thijssen J.H., Slee P.H., Blankenstein R.A. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res. 57:1997;2109-2111.
9. Geisler J., Detre S., Berntsen H., Ottestad L., Lindtjorn B., Dowsett M., Eystein Lønning P. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin. Cancer Res. 7:2001;1230-1236.
10. W.R. Miller, J.M. Dixon, M. Stuart, T. Sahmoud, Anastrozole ('Arimidex') blocks estrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer, in: Proceedings of the American Association for Cancer Research, 2000.
11. Reed M.J., Aherne G.W., Ghilchik M.W., Patel S., Chakraborty J. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int. J. Cancer. 49:1991;562-565.
12. Thijssen J.H., Blankenstein M.A., Donker G.H., Daroszewski J. Endogenous steroid hormones and local aromatase activity in the breast. J. Steroid Biochem. Mol. Biol. 39:1991;799-804.
13. Recchione C., Venturelli E., Manzari A., Cavalleri A., Martinetti A., Secreto G. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J. Steroid Biochem. Mol. Biol. 52:1995;541-546.
14. Geisler J., Berntsen H., Lonning P.E. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J. Steroid Biochem. Mol. Biol. 72:2000;259-264.
15. W. Yue, S.J. Santner, S. Masamura, J.P. Wang, L.M. Demers, C. Hamilton, R.J. Santen, Determinants of tissue estradiol levels and biologic responsiveness in breast tumors, Breast Cancer Res. Treat. 49 (Suppl. 1) (1998) S1-S7, discussion S33-S37.
16. Bonney R.C., Scanlon M.J., Reed M.J., Jones D.L., Beranek P.A., James V.H. Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism. J. Steroid Biochem. 20:1984;501-504.
17. Masamura S., Santner S.J., Gimotty P., George J., Santen R.J. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res. Treat. 42:1997;215-226.
18. Miller W.R. Pathways of hormone metabolism in normal and nonneoplastic breast tissue. Ann. N.Y. Acad. Sci. 586:1990;53-59.
19. Miller W.R., Hawkins R.A., Forrest A.P. Significance of aromatase activity in human breast cancer. Cancer Res. 42:1982;3365s-3368s.
20. Santen R.J., Leszczynski D., Tilson-Mallet N., Feil P.D., Wright C., Manni A., Santner S.J. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann. N.Y. Acad. Sci. 464:1986;126-137.
21. Santner S.J., Feil P.D., Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase-pathway. J. Clin. Endocrinol. Metab. 59:1984;29-33.
22. Miller W.R., Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J. Steroid Biochem. Mol. Biol. 79:2001;93-102.
23. Miller W.R., Forrest A.P. Oestradiol synthesis by a human breast carcinoma. Lancet. 2:1974;866-868.
24. Chen S., Zhou D., Yang C., Okubo T., Kinoshita Y., Yu B., Kao Y.C., Itoh T. Modulation of aromatase expression in human breast tissue. J. Steroid Biochem. Mol. Biol. 79:2001;35-40.
25. Zhao Y., Agarwal V.R., Mendelson C.R., Simpson E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 137:1996;5739-5742.
26. Simpson E.R., Zhao Y., Agarwal V.R., Michael M.D., Bulun S.E., Hinshelwood M.M., Graham-Lorence S., Sun T., Fisher C.R., Qin K., Mendelson C.R. Aromatase expression in health and disease. Rec. Prog. Horm. Res. 52:1997;185-213. (discussion 184-213).
27. Simpson E.R., Michael M.D., Agarwal V.R., Hinshelwood M.M., Bulun S.E., Zhao Y. Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J. 11:1997;29-36.
28. Agarwal V.R., Bulun S.E., Leitch M., Rohrich R., Simpson E.R. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab. 81:1996;3843-3849.
29. N. Harada, T. Utsumi, Y. Takagi, Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer, Pharmacogenetics, 5 (1995) (Spec. No. S59-S64).
30. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P.O., Lonning P.E. Influence of anastrozole (Arimidex): a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer. 74:1996;1286-1291.
31. Dowsett M., Jones A., Johnston S.R., Jacobs S., Trunet P., Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res. 1:1995;1511-1515.
32. Geisler J., Haynes B., Anker G., Dowsett M., Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20:2002;751-757.
33. Geisler J., King N., Anker G., Ornati G., Di Salle E., Lonning P.E., Dowsett M. In vivo inhibition of aromatization by exemestane a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. 4:1998;2089-2093.
34. Miller W.R., Telford J., Love C.D., Leonard R., Hillier S., Grundacker H., Smith H., Dixon J.M. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. The Breast. 7:1998;273-276.
35. W.R. Miller, M. Stuart, T. Sahmoud, M. Dixon, Anastrozole ('Arimidex') blocks estrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancers, in: Proceedings of the American Association for Cancer Research, 2000, pp. 4707.
36. MacIndoe J.H. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology. 123:1988;1281-1287.
37. Hawkins R.A., Thomson M.L., Killen E. Oestrone sulphate, adipose tissue, and breast cancer. Breast Cancer Res. Treat. 6:1985;75-87.
38. Adams J.B., Pewnim T., Chandra D.P., Archibald L., Foo M.S. A correlation between estrogen sulfotransferase levels and estrogen receptor status in human primary breast carcinoma. Cancer Res. 39:1979;5124-5126.
39. Dao T.L., Hayes C., Libby P.R. Steroid sulfatase activities in human breast tumors. Proc. Soc. Exp. Biol. Med. 146:1974;381-384.
40. Pasqualini J.R., Cortes-Prieto J., Chetrite G., Talbi M., Ruiz A. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int. J. Cancer. 70:1997;639-643.
41. Utsumi T., Yoshimura N., Takeuchi S., Ando J., Maruta M., Maeda K., Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 59:1999;377-381.
42. Pasqualini J.R., Gelly C., Nguyen B.L., Vella C. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34:1989;155-163.
43. Santen R.J., Martel J., Hoagland M., Naftolin F., Roa L., Harada N., Hafer L., Zaino R., Santner S.J. Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 79:1994;627-632.
44. Tobacman J.K., Hinkhouse M., Khalkhali-Ellis Z. Steroid sulfatase activity and expression in mammary myoepithelial cells. J. Steroid Biochem. Mol. Biol. 81:2002;65-68.
45. Pasqualini J.R., Chetrite G., Nguyen B.L., Maloche C., Delalonde L., Talbi M., Feinstein M.C., Blacker C., Botella J., Paris J. Estrone sulfate-sulfatase and 17beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid Biochem. Mol. Biol. 53:1995;407-412.
46. Masamura S., Santner S.J., Santen R.J. Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J. Steroid Biochem. Mol. Biol. 58:1996;425-429.
47. Purohit A., Riaz A.A., Ghilchik M.W., Reed M.J. The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women. Horm. Metab. Res. 24:1992;532-536.
48. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
49. Dexter D.W., Reddy R.K., Geles K.G., Bansal S., Myint M.A., Rogakto A., Leighton J.C., Goldstein L.J. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin. Cancer Res. 4:1998;1533-1542.
50. Tamai I., Nezu J., Uchino H., Sai Y., Oku A., Shimane M., Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:2000;251-260.
51. Krazeisen A., Breitling R., Moller G., Adamski J. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5. Mol. Cell. Endocrinol. 171:2001;151-162.
52. Dufort I., Rheault P., Huang X.F., Soucy P., Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology. 140:1999;568-574.
53. Pollow K., Boquoi E., Baumann J., Schmidt-Gollwitzer M., Pollow B. Comparison of the in vitro conversion of estradiol-17beta to estrone of normal and neoplastic human breast tissue. Mol. Cell. Endocrinol. 6:1977;333-348.
54. Miettinen M., Mustonen M., Poutanen M., Isomaa V., Wickman M., Soderqvist G., Vihko R., Vihko P. 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Res. Treat. 57:1999;175-182.
55. Adamski J., Jakob F.J. A guide to 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 171:2001;1-4.
56. Poutanen M., Isomaa V., Lehto V.P., Vihko R. Immunological analysis of 17beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int. J. Cancer. 50:1992;386-390.
57. Isomaa V.V., Ghersevich S.A., Maentausta O.K., Peltoketo E.H., Poutanen M.H., Vihko R.K. Steroid biosynthetic enzymes: 17beta-hydroxysteroid dehydrogenase. Ann. Med. 25:1993;91-97.
58. Poutanen M., Isomaa V., Peltoketo H., Vihko R. Role of 17beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J. Steroid Biochem. Mol. Biol. 55:1995;525-532.
59. Sasano H., Frost A.R., Saitoh R., Harada N., Poutanen M., Vihko R., Bulun S.E., Silverberg S.G., Nagura H. Aromatase and 17beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J. Clin. Endocrinol. Metab. 81:1996;4042-4046.
60. Santner S.J., Leszczynski D., Wright C., Manni A., Feil P.D., Santen R.J. Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res. Treat. 7:1986;35-44.
61. Miettinen M.M., Mustonen M.V., Poutanen M.H., Isomaa V.V., Vihko R.K. Human 17beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem. J. 314(Part 3):1996;839-845.
62. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue. Cancer Res. 45:1985;2907-2912.
63. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 19:1998;1-27.
64. C.R. Jefcoate, J.G. Liehr, R.J. Santen, T.R. Sutter, J.D. Yager, W. Yue, S.J. Santner, R. Tekmal, L. Demers, R. Pauley, F. Naftolin, G. Mor, L. Berstein, Tissue-specific synthesis and oxidative metabolism of estrogens, J. Natl. Cancer Inst. Monogr. (2000) 95-112.
65. Bradlow H.L., Hershcopf R., Martucci C., Fishman J. 16 alpha-hydroxylation of estradiol: a possible risk marker for breast cancer. Ann. N.Y. Acad. Sci. 464:1986;138-151.
66. Telang N.T., Axelrod D.M., Wong G.Y., Bradlow H.L., Osborne M.P. Biotransformation of estradiol by explant culture of human mammary tissue. Steroids. 56:1991;37-43.
67. Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 93:1996;3294-3296.
68. van Landeghem A.A., Poortman J., Helmond-Agema A., Thijssen J.H. Measurement of endogenous subcellular concentration of steroids in tissue. J. Steroid Biochem. 20:1984;639-644.
69. Johannessen D.C., Engan T., Di Salle E., Zurlo M.G., Paolini J., Ornati G., Piscitelli G., Kvinnsland S., Lonning P.E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin. Cancer Res. 3:1997;1101-1108.
70. James V.H., Reed M.J., Lai L.C., Ghilchik M.W., Tait G.H., Newton C.J., Coldham N.G. Regulation of estrogen concentrations in human breast tissues. Ann. N.Y. Acad. Sci. 595:1990;227-235.
71. Geisler J., Lonning P.E. Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. Clin. Breast Cancer. 1:2001;297-308. (discussion 309).